Stock RICHTER GEDEON RICHTER
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gedeon Richter

Equities

RICHTER

HU0000123096

Pharmaceuticals

End-of-day quote Budapest S.E.
Other stock markets
 03:30:00 19/06/2024 am IST 		5-day change 1st Jan Change
9,270 HUF -0.59% Intraday chart for Gedeon Richter +0.32% +5.94%
31/05 Gedeon Richter Plc. Approves Dividend Payment in Respect of the 2023 Financial Year CI
22/05 Gedeon Richter plc announces Directorate Changes CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 11,93,129 13,81,559 16,19,625 15,42,290 16,27,029 16,94,305 - -
Enterprise Value (EV) 1 10,62,663 12,39,491 15,59,769 13,95,557 15,46,536 15,67,013 14,99,404 13,44,409
P/E ratio 24.2 x 13.2 x 11.6 x 9.94 x 10.2 x 7.02 x 6.41 x 5.48 x
Yield 0.98% 3.02% 2.58% 4.7% - 6.03% 6.39% 7.55%
Capitalization / Revenue 2.35 x 2.44 x 2.57 x 1.92 x 2.02 x 2.05 x 1.85 x 1.68 x
EV / Revenue 2.09 x 2.19 x 2.47 x 1.74 x 1.92 x 1.89 x 1.64 x 1.33 x
EV / EBITDA 9.53 x 8.19 x 8.86 x 7.1 x 6.43 x 4.83 x 3.99 x 3.29 x
EV / FCF 26.1 x 18.3 x -460 x 12.3 x 17.9 x 9.82 x 7.9 x 6.18 x
FCF Yield 3.83% 5.47% -0.22% 8.12% 5.6% 10.2% 12.7% 16.2%
Price to Book 1.66 x 1.72 x 1.78 x 1.47 x - 1.34 x 1.24 x 1.07 x
Nbr of stocks (in thousands) 1,85,991 1,85,693 1,85,630 1,85,818 1,85,946 1,82,773 - -
Reference price 2 6,415 7,440 8,725 8,300 8,750 9,270 9,270 9,270
Announcement Date 07/02/20 26/02/21 02/03/22 28/02/23 29/02/24 - - -
1HUF in Million2HUF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,07,794 5,66,776 6,30,595 8,02,755 8,05,158 8,26,995 9,14,452 10,07,751
EBITDA 1 1,11,534 1,51,330 1,76,123 1,96,480 2,40,625 3,24,590 3,75,410 4,08,962
EBIT 1 71,863 1,11,484 1,35,832 1,53,555 1,89,817 2,63,627 3,03,741 3,36,979
Operating Margin 14.15% 19.67% 21.54% 19.13% 23.58% 31.88% 33.22% 33.44%
Earnings before Tax (EBT) 1 51,697 1,15,164 1,46,575 1,65,663 1,71,540 2,99,279 3,19,072 3,79,742
Net income 1 49,299 1,04,683 1,39,626 1,55,581 1,58,850 2,42,144 2,68,837 3,23,776
Net margin 9.71% 18.47% 22.14% 19.38% 19.73% 29.28% 29.4% 32.13%
EPS 2 265.0 563.0 751.0 835.0 860.0 1,320 1,447 1,691
Free Cash Flow 1 40,688 67,757 -3,393 1,13,348 86,554 1,59,535 1,89,741 2,17,468
FCF margin 8.01% 11.95% -0.54% 14.12% 10.75% 19.29% 20.75% 21.58%
FCF Conversion (EBITDA) 36.48% 44.77% - 57.69% 35.97% 49.15% 50.54% 53.18%
FCF Conversion (Net income) 82.53% 64.73% - 72.85% 54.49% 65.88% 70.58% 67.17%
Dividend per Share 2 63.00 225.0 225.0 390.0 - 558.7 592.5 699.9
Announcement Date 07/02/20 26/02/21 02/03/22 28/02/23 29/02/24 - - -
1HUF in Million2HUF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1
Net sales 1 2,78,692 2,96,803 1,57,518 1,76,274 1,68,057 1,92,923 2,17,807 2,23,968 2,09,653 2,03,783 4,13,436 1,88,544 2,03,178 2,03,432
EBITDA 1 75,796 80,719 42,943 52,461 - 64,033 77,353 11,597 65,277 52,831 1,18,108 61,657 59,078 75,175
EBIT 1 55,935 60,800 33,134 41,898 - 51,972 64,840 -740 54,131 40,882 95,013 49,398 44,974 63,607
Operating Margin 20.07% 20.48% 21.04% 23.77% - 26.94% 29.77% -0.33% 25.82% 20.06% 22.98% 26.2% 22.14% 31.27%
Earnings before Tax (EBT) - - - 48,416 - - 87,457 -43,741 - - - - - -
Net income 1 60,531 54,915 - 46,518 37,906 76,532 82,417 -40,422 39,036 28,743 67,936 - - 68,217
Net margin 21.72% 18.5% - 26.39% 22.56% 39.67% 37.84% -18.05% 18.62% 14.1% 16.43% - - 33.53%
EPS - - - 250.0 - 411.0 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 03/08/20 03/08/21 08/11/21 02/03/22 09/05/22 03/08/22 07/11/22 28/02/23 12/05/23 04/08/23 04/08/23 08/11/23 29/02/24 14/05/24
1HUF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,30,466 1,42,068 59,856 1,46,733 80,493 1,27,291 1,94,900 3,49,896
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 40,688 67,757 -3,393 1,13,348 86,554 1,59,535 1,89,741 2,17,468
ROE (net income / shareholders' equity) 9.7% 13.7% 16.2% 15.8% 14.5% 17.7% 18.4% 19.4%
ROA (Net income/ Total Assets) 9.7% 11.6% 13.3% - 11.7% 17% 18% 18%
Assets 1 5,08,169 9,03,624 10,46,939 - 13,57,495 14,24,379 14,93,536 17,98,754
Book Value Per Share 2 3,874 4,333 4,910 5,633 - 6,922 7,486 8,647
Cash Flow per Share 2 528.0 723.0 752.0 992.0 670.0 1,556 1,458 1,661
Capex 1 57,552 66,638 1,43,297 71,579 94,639 93,350 88,152 93,702
Capex / Sales 11.33% 11.76% 22.72% 8.92% 11.75% 11.29% 9.64% 9.3%
Announcement Date 07/02/20 26/02/21 02/03/22 28/02/23 29/02/24 - - -
1HUF in Million2HUF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gedeon Richter

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9,270 HUF
Average target price
11,800 HUF
Spread / Average Target
+27.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
GEDEON RICHTER Stock Gedeon Richter
+5.94% 4.59B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+16.80% 43.26B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+17.47% 21.6B
SANDOZ GROUP AG Stock Sandoz Group AG
+21.62% 15.93B
CIPLA LIMITED Stock Cipla Limited
+23.95% 15.1B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.96% 12.95B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-16.22% 6.29B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+19.77% 6.04B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RICHTER Stock
  4. Financials Gedeon Richter